Severe adverse systemic drug events occur commonly as a result of treatment of cancer
patients. Nephrotoxicity of chemotherapeutic agents remains a significant complication …

The association between chronic kidney disease (CKD) and renal cell carcinoma (RCC) is
bidirectional and multifactorial. Risk factors such as hypertension, diabetes mellitus, obesity …

Aims Agents targeting vascular endothelial growth factor (VEGF) have increasingly been
used for the treatment of advanced malignancies, and have been found to induce renal …

With the incorporation of targeted therapies in routine cancer therapy, it is imperative that the
array of toxicities associated with these agents be well-recognized and managed, especially …

The prevalence of CKD may be higher in patients with cancer than in those without due to
the addition of cancer-specific risk factors to those already present for CKD. In this review …

Introduction Interferon (IFN)-α and IFN-β approved for treatment of chronic hepatitis C viral
infection and multiple sclerosis respectively have been linked to thrombotic microangiopathy …

Renal cell carcinoma (RCC) diagnosis is mostly achieved incidentally by imaging provided
for unrelated clinical reasons. The surgical management of localized tumors has reported …

Angiogenesis and immunosuppression are closely related pathophysiologic processes.
Widely prescribed in malignant tumor and proliferative retinal lesions, VEGF signaling …

Carfilzomib (CFZ) is a non-reversible proteasome inhibitor approved for the treatment of
patients with relapsed and refractory myeloma (RRMM). Its use has been associated with …

The ubiquitin proteasome pathway plays a key role in cell cycle, function and survival.
Bortezomib (BTZ) and Carfilzomib (CFZ) are the first two inhibitors of the proteasome …